Ovid Therapeutics (OVID) Return on Sales (2020 - 2026)

Ovid Therapeutics' Return on Sales history runs 7 years deep, the most recent figure standing at 0.03% for Q1 2026.

• Quarterly Return on Sales rose 75.0% year-over-year to 0.03% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.03% (up 42.0% YoY) and the FY2025 annual result came in at 0.02%, up 44.0% from the prior year.
• Return on Sales was 0.03% for Q1 2026 at Ovid Therapeutics, down from 0.13% in the prior quarter.
• Across five years, Return on Sales topped out at 0.5% in Q2 2024 and bottomed at 10.78% in Q3 2022.
• A 5-year average of 1.39% and a median of 0.81% in 2024 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2022 — Return on Sales sank 1079 bps — and 2023, when it jumped 975 bps.
• Ovid Therapeutics' Return on Sales stood at 2.49% in 2022, then soared by 57 bps to 1.08% in 2023, then decreased by 13 bps to 1.22% in 2024, then soared by 111 bps to 0.13% in 2025, then sank by 125 bps to 0.03% in 2026.
• Business Quant data shows OVID's Return on Sales at 0.03% in Q1 2026, 0.13% in Q4 2025, and 0.92% in Q3 2025.